Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2023-12-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
第三届监事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the ninth meeting of the third Supervisory Board of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, and voting results on the use of temporarily idle raised funds for cash management. The document is an official meeting resolution announcement rather than a full report or financial statement. It does not contain financial data or detailed management discussion but rather the outcome of a board meeting. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies. The document length is short (1043 characters), and it is not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2023-12-22 Chinese
董事会战略与投资委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board Strategic and Investment Committee Work Rules" of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the establishment, composition, responsibilities, meeting rules, and procedural guidelines of a board committee. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, no executive compensation, and no regulatory filings. The content is focused on governance structure and internal board committee rules. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 1909 characters, which is short but contains substantive governance content, not just an announcement or notice. Therefore, the appropriate classification is CGR with high confidence.
2023-12-22 Chinese
公司章程
Governance Information Classification · 100% confidence The document is a detailed corporate charter or articles of association for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes chapters on general provisions, business scope, shares, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, audit, notices and announcements, mergers, amendments to the charter, and other corporate governance matters. It references Chinese company law, securities law, and stock exchange listing rules. The content is focused on the company's internal governance structure, shareholder rights, board and management roles, meeting procedures, share issuance and transfer rules, and other governance-related regulations. There is no financial data, earnings information, audit report, or announcement of voting results. The document is not a report of financial performance or a regulatory filing announcement but a comprehensive governance document. Therefore, the most appropriate classification is Governance Information (CGR).
2023-12-22 Chinese
董事会薪酬与考核委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Remuneration and Assessment Committee Work Rules" of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the structure, responsibilities, and procedures of the remuneration and assessment committee of the board, including rules on remuneration policies, assessment standards, committee composition, meeting procedures, and confidentiality. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, no earnings release, and no investor presentation. The document is a governance-related internal rules document about board and management remuneration and assessment practices. Therefore, it fits the category of Governance Information (CGR). The document length is under 5,000 characters, but it is a substantive governance policy document, not a mere announcement of a report publication or certification. Hence, the correct classification is CGR with high confidence.
2023-12-22 Chinese
关于使用自有闲置资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the use of idle funds for cash management. It details the investment purpose, amount, types of investments, risk control measures, and the approval process including board and shareholder meetings. The document is a formal disclosure about a financing activity related to cash management and investment of idle funds, not a financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather an update on capital usage and authorization. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2733 characters, which is consistent with an announcement rather than a full report.
2023-12-22 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2024年度日常关联交易预计的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the expected related party transactions for the year 2024 of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes descriptions of the related parties, transaction amounts, pricing principles, board and independent director approvals, and compliance with regulatory requirements. The document is not a full annual report or financial statement but rather a regulatory compliance and verification report related to related party transactions, which is typical for regulatory filings. The document length is 4104 characters, which is relatively short and focused on a specific regulatory matter rather than a comprehensive financial report. There is no indication that this is an announcement of a report publication or a certification letter. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a compliance-related document that does not fit into other specific categories like Annual Report or Audit Report.
2023-12-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.